Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedNew Developments in Chronic Myeloid Leukemia: Implications for TherapyAn Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsProteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunitiesc-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's DiseaseZebrafish Models of Human Leukemia: Technological Advances and Mechanistic InsightsNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionQuantitative modeling of chronic myeloid leukemia: insights from radiobiologyModulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug designA natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cellsApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaMapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemiaDetection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPETDeletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.Generation and repair of AID-initiated DNA lesions in B lymphocytes.Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature.FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution.Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.Identification of heptapeptides interacting with IFN-α-sensitive CML cells.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression dataBCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro.Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.Using functional genomics to overcome therapeutic resistance in hematological malignancies.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer.Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cellsCombined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid LeukemiaPredicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemiaChronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track.
P2860
Q26738514-8DB15162-B774-4180-A195-4CE05B9E4E27Q26745669-1E8DC31D-A8B7-4CFC-9AA6-7CCEA1AE5AA9Q26772895-8C7AFF99-1242-4671-BC3F-EA58F477A3F6Q26849792-C3360575-DC24-4EA3-9017-DE4822427328Q26861489-1F1E4878-BE98-4EF9-9B10-55430BC1C85BQ28070292-0EC1346A-1004-42D5-864A-9CE648A90D56Q28078210-DD268E20-7199-4B53-8722-74D9975F8DC4Q28082487-4FC811AB-C59D-4EDB-9D43-E7F19C2E3442Q28384954-8312AFFF-412D-4659-9260-D42A2170141AQ28472533-FAB70548-6BF7-4533-B7EF-7056E0C2CA26Q28478748-B236E3EA-985F-4EB3-B781-A9DE490B735EQ28486933-43299C3D-522D-435B-ABF0-E0BEFC7AD96CQ28534259-FD7262C3-775A-4915-ABE6-8768A9A39B83Q30009317-2506CAA5-4BC2-42C1-9F51-AC7758B231DDQ30009399-BB437D68-A9DE-4558-BDCD-7356F0FCA57FQ30432360-20F155AF-4F9C-47B5-A082-0854809D7E1EQ33524890-E366A079-9E3A-405F-99AB-73B162362C04Q33690522-1776E1C2-4765-4BDF-8F8D-34C52841FA73Q33701925-CE352A4E-D15F-4967-A366-1580733C01F2Q33728189-A32CF9F5-3DD9-49CC-9E05-446A60443BC7Q33784347-8901D391-6948-4E74-838D-C9866ED8CF69Q33878774-15D636F1-0965-4D3F-BFF1-BC2026322E82Q33905061-83359AD1-34A2-47F6-904C-2B962C5E5C0AQ33944952-ADDD11B3-279B-4CC2-8C43-0E4A7B9E500FQ34031967-045E20D2-F3DD-4E51-B747-C61906E255D9Q34076524-EB49218A-2247-4D11-BA38-3DDD69568E50Q34121339-E45118B2-753B-4860-BDD7-55C8635ED480Q34148173-4141557E-ED7E-431B-A23E-39F57598C639Q34181572-287B03F4-8C1E-4BB4-9C44-5A8B00B0B4E8Q34190803-E45FB435-999D-4EFC-97ED-BCE990C5AA13Q34213580-BD0CCFF7-EA6D-4D9F-9429-CD9F36ACA9E9Q34392064-753CF15D-127A-41B4-9C92-3FA5A2EC32FBQ34401328-22BC026F-A9E7-4659-9B86-1BEB470BCFA1Q34417824-B68069CE-AC34-4AB3-86CD-257A8425DA2EQ34469351-22453039-D063-43D5-8D85-44A160D0BA7AQ34483497-47490096-0FC5-4506-9D76-89D4B0956DEDQ34521001-B45CAD9F-8702-4732-A620-B2DC0B7189B9Q34572279-A2794B7B-EE1F-46FD-823B-00EDCC5B8051Q34642865-01F7F7EE-0336-4176-8FE8-89C442C7A133Q34663279-535930D3-F36A-4610-BF4E-159F5B3BE212
P2860
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@en
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@nl
type
label
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@en
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@nl
prefLabel
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@en
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@nl
P2860
P1433
P1476
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
@en
P2093
Alfonso Quintás-Cardama
P2860
P304
P356
10.1182/BLOOD-2008-03-144790
P407
P577
2008-09-30T00:00:00Z